Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Gastroenterology
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
Iron-enriched microgreens in smoothies for 28 days improve iron levels in women, assessed via blood tests and dietary tracking.
30 Apr 2026 NCT06972927
active not recruiting Phase II
A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
A study testing a new antibody drug to block myostatin in adults with facioscapulohumeral muscular dystrophy.
30 Apr 2026 NCT05548556
active not recruiting Diabetes / Metabolic
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
Real-world study collecting data on vision outcomes in patients with wet macular degeneration or diabetic eye swelling treated with aflibercept 8mg injections.
30 Apr 2026 NCT06075147
active not recruiting Phase IV
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Faricimab injections given every 24 weeks or less maintain vision in treatment-naive wet age-related macular degeneration over 100 weeks.
30 Apr 2026 NCT06795048
active not recruiting Oncology
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
Cabozantinib plus nivolumab as first-line treatment for advanced kidney cancer: real-world safety and effectiveness study.
30 Apr 2026 NCT05361434
● Recruiting Phase III Oncology
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Treatment being tested: Sacituzumab govitecan-hziy (an antibody-drug conjugate targeting Trop-2) combined with pembrolizumab (PD-L1 inhibitor) versus physician's choice treatment in the adjuvant setting following…
30 Apr 2026 NCT05633654
● Recruiting Oncology
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
What is being tested: SGLT2 inhibitors are being investigated as a potential preventive or therapeutic intervention for anthracycline-induced cardiotoxicity, a serious heart damage complication…
30 Apr 2026 NCT07070765
● Recruiting Gastroenterology
Drug-induced Liver Injury: Itching Study
What is being tested: The study investigates itching (pruritus) associated with drug-induced liver injury (DILI), specifically focusing on cholestatic or mixed-pattern hepatic reactions—an unpredictable…
30 Apr 2026 NCT06446609
● Recruiting Phase III Oncology
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
What is being tested: Paltusotine, an oral daily medication, is being evaluated against placebo in a Phase 3 randomized controlled trial to assess its…
30 Apr 2026 NCT07087054
● Recruiting Phase III Oncology
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Treatment Being Tested: Ivonescimab (a dual TIGIT/PD-L1 pathway inhibitor) combined with chemotherapy compared to pembrolizumab (PD-L1 inhibitor) combined with chemotherapy as first-line therapy for…
30 Apr 2026 NCT05899608
● Recruiting Cardiology / Cardiovascular
Rebalancing the Fat Content of the Heart and Muscles
What is being tested: Semaglutide's effects on reducing fat accumulation in the heart and skeletal muscles, beyond its traditional role in blood sugar control…
30 Apr 2026 NCT07065383
● Recruiting Cardiology / Cardiovascular
Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
What is being tested: Manganese-enhanced Magnetic Resonance Imaging (MEMRI) as a novel imaging technique to visualise cardiac function and myocardial viability in heart failure…
30 Apr 2026 NCT06652763
● Recruiting Phase III Cardiology / Cardiovascular
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Treatment being tested: ADX-324 is a novel therapy being evaluated for long-term safety and efficacy in hereditary angioedema (HAE) Types I and II, building…
30 Apr 2026 NCT07428499
● Recruiting Cardiology / Cardiovascular
The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
What is being tested: The relationship between epicardial adiposity (fat surrounding the heart) and heart failure with preserved ejection fraction (HFpEF), using advanced imaging…
30 Apr 2026 NCT06768437
● Recruiting Cardiology / Cardiovascular
Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy
What is being tested: The study investigates whether genetic factors predispose certain individuals to developing takotsubo cardiomyopathy (stress-induced cardiomyopathy), rather than this condition occurring…
30 Apr 2026 NCT04513054
● Recruiting Cardiology / Cardiovascular
Non-invasive Diagnosis of Coronary Microvascular Disease: Pilot Study
What is being tested: Non-invasive diagnostic methods to identify coronary microvascular disease (CMD) in patients with angina symptoms but no significant blockage in main…
30 Apr 2026 NCT06070662
● Recruiting Phase III Oncology
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
What is being tested: AZD0120, a dual-targeted CAR-T cell therapy targeting both BCMA and CD19 antigens, is being compared against standard chemotherapy regimens (daratumumab-based…
30 Apr 2026 NCT07391657
● Recruiting Phase III Oncology
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
What is being tested: Quizartinib (a FLT3 inhibitor) plus standard chemotherapy versus placebo plus chemotherapy in newly diagnosed FLT3-ITD negative AML patients to determine…
30 Apr 2026 NCT06578247
● Recruiting Phase I Oncology
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
What is being tested: EG-70 is an intravesical immunotherapy being evaluated for safety and efficacy in non-muscle invasive bladder cancer (NMIBC), with a Phase…
30 Apr 2026 NCT04752722
● Recruiting Phase III Oncology
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
What is being tested: A randomised comparison of two triple-drug regimens—mezigdomide (a novel cereblon modulator) combined with bortezomib and dexamethasone versus the established pomalidomide…
30 Apr 2026 NCT05519085
active not recruiting Phase III
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
Long-term safety and effectiveness study of ianalumab, a new drug treatment for patients with Sjögren's syndrome.
29 Apr 2026 NCT05985915
● Recruiting Phase II
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Alpelisib (a targeted drug) tested in children and adults with PIK3CA gene mutations causing abnormal tissue overgrowth.
29 Apr 2026 NCT06997588
● Recruiting Phase III
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Iptacopan reduces kidney damage better than placebo in patients with a specific type of glomerulonephritis.
29 Apr 2026 NCT05755386
● Recruiting Phase III
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Study testing intravenous efgartigimod versus placebo in adults with immune thrombocytopenia to assess effectiveness and safety.
29 Apr 2026 NCT06544499
● Recruiting Phase III
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Xeomin injections tested against placebo for reducing monthly migraine days in chronic migraine patients over one year.
29 Apr 2026 NCT07018713
active not recruiting Phase III Neurology
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
ZX008 reduced seizures in children and adults with CDKL5 deficiency disorder compared to placebo.
29 Apr 2026 NCT05064878
active not recruiting Phase III Dermatology
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
52-week trial testing whether continuing or increasing ritlecitinib dosing maintains or improves skin pigmentation recovery in non-segmental vitiligo patients.
29 Apr 2026 NCT06163326
active not recruiting Phase II Oncology
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Three immunotherapy combinations tested in chemotherapy-ineligible patients with advanced bladder cancer: LAG-3 alone, LAG-3 plus TIGIT inhibitor, versus PD-L1 inhibitor.
29 Apr 2026 NCT05645692
● Recruiting Phase IV
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
Long-term follow-up of an eye implant treatment for MacTel type 2, including patients who previously received sham surgery.
29 Apr 2026 NCT06971939
active not recruiting
PERIGON Pivotal Trial
PERIGON Trial Summary Study testing whether a new artificial heart valve (Model 400) is safe and effective for patients needing aortic valve replacement.
29 Apr 2026 NCT02088554
● Recruiting Phase II Rheumatology
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
Intervention being tested: Faecal Microbiota Transplant (FMT) versus placebo in patients with primary sclerosing cholangitis (PSC), a rare autoimmune liver disease with no established…
29 Apr 2026 NCT06286709
● Recruiting Phase I Respiratory / COPD / Asthma
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
What is being tested: LTP001 is a novel investigational treatment being evaluated in a two-part study: Part A assesses safety and tolerability in healthy…
29 Apr 2026 NCT06649110
● Recruiting Phase I Respiratory / COPD / Asthma
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
GSK4527363 is a novel investigational agent being evaluated for safety, tolerability, and pharmacokinetic/pharmacodynamic properties across healthy volunteers and patients with SLE and connective tissue…
29 Apr 2026 NCT06576271
● Recruiting Phase II Respiratory / COPD / Asthma
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
What is being tested: Long-term safety and efficacy outcomes of Avalyn's inhaled antifibrotic agent (AP01) in participants who previously completed earlier phase trials, using…
29 Apr 2026 NCT06951217
● Recruiting Cardiology / Cardiovascular
Hypertension Management in Young Adults Personalised by Echocardiography and Clinical Outcome.
What is being tested: Baseline transthoracic echocardiography combined with routine hypertension clinic data to guide personalised management and improve cardiovascular risk stratification in young…
29 Apr 2026 NCT03762499
● Recruiting Cardiology / Cardiovascular
Hypertension Explored in Long-term Postpartum Follow-up in Later Life
What is being tested: The study investigates the long-term cardiovascular mechanisms linking hypertensive pregnancy disorders (gestational hypertension and preeclampsia) to increased risk of chronic…
29 Apr 2026 NCT06187012
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
What is being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) versus placebo in hospitalized patients with acute decompensated heart failure, specifically targeting those with…
29 Apr 2026 NCT06008197
● Recruiting Cardiology / Cardiovascular
BoStOn SCientific Rhythm MAnagemenT REgiStry (SOCRATES)
What is being tested: SOCRATES is a post-market surveillance registry monitoring Boston Scientific's rhythm management devices (pacemakers, defibrillators, and related systems) to evaluate real-world…
29 Apr 2026 NCT04823663
● Recruiting Cardiology / Cardiovascular
Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies
What is being tested: The role of tetrahydrofolate (active folate) supplementation in reducing adverse outcomes in pregnant women with hypertension, investigating whether enhanced folate…
29 Apr 2026 NCT05434195
● Recruiting Phase III Oncology
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Intervention being tested: Sacituzumab govitecan (an antibody-drug conjugate targeting Trop-2) compared against standard of care chemotherapy in patients with previously treated extensive-stage small cell…
29 Apr 2026 NCT06801834
● Recruiting Phase I Oncology
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Treatment being tested: Investigational agents administered alone or in combination with pembrolizumab (a PD-1 inhibitor) in patients with PD-1/L1-refractory urothelial carcinoma, addressing an unmet…
29 Apr 2026 NCT05562830
● Recruiting Phase III Oncology
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
What is being tested: Datopotamab deruxtecan (Dato-DXd), a TROP2-targeted antibody-drug conjugate, is being compared against standard docetaxel chemotherapy in previously treated advanced/metastatic non-squamous NSCLC…
29 Apr 2026 NCT07291037
● Recruiting Phase III
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Ravulizumab drug reduced need for dialysis after kidney transplant compared to placebo in high-risk patients.
28 Apr 2026 NCT06830798
● Recruiting Rheumatology
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
PROMISSE Study Summary Blood markers (complement products and antiangiogenic factors) may predict pregnancy complications in SLE and antiphospholipid syndrome patients.
28 Apr 2026 NCT00198068
● Recruiting Diabetes / Metabolic
Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults
Testing whether leucine-enriched whey protein boosts muscle protein production in older adults at rest and after exercise, compared to standard whey protein.
28 Apr 2026 NCT06971822
● Recruiting Phase III
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Enlicitide added to rosuvastatin reduced cholesterol more than rosuvastatin alone in high cholesterol patients.
28 Apr 2026 NCT07216482
active not recruiting Phase I Oncology
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Trial testing immune-boosting antibodies plus cetuximab for advanced head and neck cancer patients who've failed standard treatment.
28 Apr 2026 NCT05249426
active not recruiting Phase I Rheumatology
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
Drug BI 3000202 safety and tolerability trial in adults with type 1 interferonopathies including AGS, COPA, and FCL syndromes.
28 Apr 2026 NCT06878365
● Recruiting Phase II
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
This trial tests whether a new medicine (PGN-EDODM1) is safe and works for people with myotonic dystrophy type 1.
28 Apr 2026 NCT06667453
● Recruiting Rare Diseases
Pompe Disease Registry Protocol
Global registry tracking Pompe disease progression and treatment outcomes in patients to improve diagnosis, monitoring, and therapeutic guidance.
28 Apr 2026 NCT00231400